Press Releases

May 24, 2018
Protagonist Therapeutics Names Samuel Saks, M.D., as Chief Development Officer Read More
May 17, 2018
Protagonist Therapeutics Announces Two Oral Presentations Accepted for 23rd Congress of the European Hematology Association Read More
May 16, 2018
Protagonist Therapeutics Appoints Bryan Giraudo to Board of Directors Read More
March 26, 2018
Protagonist Therapeutics Discontinues Phase 2b PROPEL Trial of PTG-100 for the Treatment of Ulcerative Colitis following Interim Analysis Read More
March 9, 2018
Protagonist Therapeutics to Participate in the 28th Annual Oppenheimer Healthcare Conference Read More
March 7, 2018
Protagonist Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results Read More
March 6, 2018
FDA Grants Orphan Drug Designation for Protagonist Therapeutics' PTG-300 for the Treatment of Beta-Thalassemia Read More
March 1, 2018
Protagonist Therapeutics to Participate in the Barclay's Global Healthcare Conference Read More
March 1, 2018
Protagonist to Announce Fourth Quarter and Year-End 2017 Financial Results on March 7, 2018; Year-End Update Call to Follow Read More
January 31, 2018
Protagonist Therapeutics to Participate in the Leerink Partners 7th Annual Global Healthcare Conference Read More
January 4, 2018
Protagonist Therapeutics Granted Two New US Patents for Peptide Drug Candidates PTG-100 and PTG-300 Read More